These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28215847)

  • 1. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7.
    Scott E; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Urol Oncol; 2017 Mar; 35(3):120. PubMed ID: 28215847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
    Nordström T; Adolfsson J; Grönberg H; Eklund M
    BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.
    Eklund M; Nordström T; Aly M; Adolfsson J; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Presti JC; StLezin M; Clements M; Egevad L; Grönberg H
    Eur Urol Focus; 2018 Sep; 4(5):707-710. PubMed ID: 28753803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.
    Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG;
    Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
    Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
    JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
    Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
    JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI.
    Nordström T; Jäderling F; Carlsson S; Aly M; Grönberg H; Eklund M
    BMJ Open; 2019 Jun; 9(6):e027816. PubMed ID: 31201191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
    Ström P; Kartasalo K; Olsson H; Solorzano L; Delahunt B; Berney DM; Bostwick DG; Evans AJ; Grignon DJ; Humphrey PA; Iczkowski KA; Kench JG; Kristiansen G; van der Kwast TH; Leite KRM; McKenney JK; Oxley J; Pan CC; Samaratunga H; Srigley JR; Takahashi H; Tsuzuki T; Varma M; Zhou M; Lindberg J; Lindskog C; Ruusuvuori P; Wählby C; Grönberg H; Rantalainen M; Egevad L; Eklund M
    Lancet Oncol; 2020 Feb; 21(2):222-232. PubMed ID: 31926806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7.
    Nordström T; Eklund M; Grönberg H
    World J Urol; 2017 Jun; 35(6):895-896. PubMed ID: 27484206
    [No Abstract]   [Full Text] [Related]  

  • 15. Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model.
    Nordström T; Grönberg H; Adolfsson J; Egevad L; Aly M; Eklund M
    Eur Urol Focus; 2018 Apr; 4(3):385-387. PubMed ID: 28753831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.
    Nordström T; Akre O; Aly M; Grönberg H; Eklund M
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):57-63. PubMed ID: 29259293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
    Murray NP; Fuentealba C; Reyes E; Jacob O
    Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.